Articles tagged with Inhibitory Effects
A new review paper suggests that selective protection of normal cells from chemotherapy could increase the therapeutic window and improve outcomes for cancer patients. The authors propose using antagonistic drug combinations to kill drug-resistant cancer cells, reducing side effects and improving quality of life.
A phase 2 study found that ANGPTL3 inhibitor therapy reduced triglycerides by up to 70% in patients with severe hypertriglyceridemia who had previously experienced acute pancreatitis. The treatment, evicanumab-dgnb, also showed potential for cardiovascular prevention by reducing apolipoprotein B levels.
A new UC Davis study has identified 194 significantly different genes in the brains of people with autism, with many linked to brain connectivity, immune response, and inflammation. The research also found age-dependent differences in genes related to synaptic function and cell loss.
Phytochromes play a dual role in seed germination of Aethionema arabicum, stimulating but also inhibiting germination. The study reveals that high light intensity and duration inhibit germination, while short exposure favors germination, indicating a genetic basis for adaptation to environmental requirements.
Researchers at Washington State University found that CBD inhibits a key enzyme for nicotine metabolism, slowing down its effects and allowing smokers to wait before feeling the urge to smoke. The study suggests that CBD could be a useful tool in reducing harm from smoking and quitting nicotine addiction.
A new experimental contraceptive drug has been developed by Weill Cornell Medicine investigators, demonstrating the possibility of an on-demand male contraceptive. The study found that a single dose of the sAC inhibitor TDI-11861 temporarily stops sperm movement and prevents pregnancies in preclinical models.
Researchers investigated the effects of everolimus on the STAT3/HIF-1α/VEGF pathway in TP53 mutant cell lines and xenograft models. Everolimus treatment significantly inhibited cell growth and reduced tumor angiogenesis and lymphangiogenesis.
Researchers found that regorafenib, a dual PDGFR α/β inhibitor, modifies the cancer microenvironment and enhances the efficacy of anti-PD-1 immunotherapy in advanced gastric cancers. This combination therapy boosts tumor infiltrating immune cells and reduces tumor fibroblasts.
The American College of Physicians recommends bisphosphonates as initial pharmacologic treatment to reduce fracture risk in osteoporosis patients. Long-term use may increase risks, so treatment duration should be limited to 5 years or less.
A new study reveals ketamine dramatically changes neuronal activity patterns in the cerebral cortex, turning off active neurons and turning on silent ones. This switch in brain activity may impact our understanding of ketamine's antidepressant effects and future research in neuropsychiatry.
Researchers found that glutaminase inhibitor BPTES selectively eliminates senescent dermal fibroblasts, improving skin aging phenotype by increasing collagen density and cell proliferation. The study suggests BPTES as a potential therapeutic agent for skin aging, offering new treatment options.
Scientists at Medical College of Georgia discover a new target to intervene in coronary artery disease, the most common type of heart disease. The target is ATIC, a gene essential for purine production, which increases in response to arterial disease.
A KAIST research team has developed a surface-lighting microLED patch for UV-induced melanogenesis inhibition. The patch demonstrated significant suppression of melanin synthesis and minimized epidermal photo-toxicity, making it a promising treatment option for skin diseases such as spots and freckles.
Researchers found two Korean native plants' saponins inhibit SARS-CoV-2 entry into cells by blocking membrane fusion. These compounds show promise in treating COVID-19, especially for asymptomatic cases.
Researchers found that MK256 induced differentiation and maturation in leukemia stem cells, inhibiting proliferation of AML cell lines. The study also showed dose-dependent inhibition of the STAT pathway in both in vitro and in vivo studies.
Researchers at the University of Helsinki have identified a promising drug candidate, TYK2 inhibitor, for preventing type 1 diabetes. The study found that inhibiting TYK2 expression reduces the destruction of pancreatic beta cells, but may also reduce beta cell production in earlier stages.
A new study has shown that SGLT-2 inhibitors, a type of diabetes medication, can decrease cardiovascular risk in adults with chronic kidney disease. The meta-analysis included results from 13 major clinical trials and found a 28% lower risk of worsening kidney disease and death from cardiovascular disease.
Researchers at Jacobs University have found that a compound in coffee, 5-caffeoylquinic acid, can inhibit the interaction between the SARS-CoV-2 spike protein and the ACE-2 receptor, potentially providing protection against COVID-19. The study's findings suggest that regular coffee drinkers may be less likely to contract the virus.
A new preclinical study discovered the underlying cause of gender differences in immunotherapy-associated myocarditis and identified potential treatment strategies. Hormone therapies targeting the endocrine-cardiac-immune pathway may reduce this risk without affecting treatment efficacy.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
A study by Hokkaido University researchers found that low concentrations of cetylpyridinium chloride in mouthwash can inhibit SARS-CoV-2 infectivity and viral load, regardless of variant. This antiviral effect is thought to be due to disruption of the lipid membrane surrounding the virus.
A study found that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells. Inhibition of EGFR by lapatinib therapy in combination with lenvatinib enhanced growth inhibitory effect and inhibited tumor growth more remarkably than monotherapy.
Researchers identified differences in PTK activity between normal and cancer kidney tissue, with Src family kinases and PI3K pathways exhibiting high activity. Ex vivo treatment of clear cell RCC with TKIs revealed that tivozanib and cabozantinib were more potent inhibitors than sunitinib or pazopanib.
A study by CNIC scientists has identified a key role for the MKK3/6–p38γ/δ signaling pathway in cardiac hypertrophy. Inhibition of p38α promotes an unexpected activation of the other branch of the pathway, consisting of the proteins MKK3, p38γ, and p38δ. This activation induces another key pathway in cardiac hypertrophy, the mTOR pathway.
Researchers investigated the effects of neoadjuvant chemoradiotherapy on CD8+ tumor-infiltrating lymphocytes, PD-L1, and mucin expression in rectal cancer patients. The study found that nCRT exposure was associated with higher mucin expression and a non-significant difference in PD-L1 expression, suggesting an immunosuppressive phenotype.
Researchers identified CUDC907 as a dual phosphoinositide-3 kinase/histone deacetylase inhibitor that promotes apoptosis in NF2 schwannoma cells. The compound reduced viability and induced cell cycle arrest in human merlin deficient Schwann cell models.
A new study found that opioids like morphine can cause gastric inflammation due to increased acid secretion and delayed gastric emptying. Treatment with naloxone or proton pump inhibitors like omeprazole may provide gastroprotection, improving pain management and reducing side effects.
Researchers uncover brain area responsible for driving action and suppressing drive in a novel task designed to study active action suppression. The team identified the dorsomedial striatum as the key region promoting action, while the indirect pathway suppresses it, leading to an 'impulsivity switch'.
Researchers used chemoproteomics to profile 53 HDAC drugs and found many had additional targets beyond their intended HDACs. The study identified MBLAC2 as a common off-target protein that affects extracellular vesicle accumulation.
A recent study at Tokyo Institute of Technology reveals that dopamine regulates insulin secretion through a complex of receptors, specifically D1 and D2. The discovery offers new insights into the mechanism behind this regulation and has potential therapeutic targets for preventing, treating, and managing diabetes.
Researchers at Tokyo University of Science identify brain regions and signaling pathways involved in fear extinction via delta receptor activation. The study suggests a potential therapeutic agent for post-traumatic stress disorders by suppressing fearful memories.
Researchers at Tokyo University of Science discovered that disulfiram inhibits FROUNT protein and chemokine signaling pathways, reducing anxiety levels in mice. The study suggests a potential breakthrough anti-anxiety medication with safe and effective treatment for elderly patients suffering from anxiety and insomnia.
Researchers identified clofarabine as a promising compound with inhibitory effects on bladder cancer cells, including urothelial carcinoma and sarcomatoid carcinoma. The study suggests potential for clinical trials to treat metastatic bladder cancer patients who cannot receive traditional cisplatin-based therapy.
The study found that patiromer significantly lowers blood potassium levels in patients taking RAASi medications for heart failure. The results suggest that patiromer can be used to control excess potassium buildup in the blood, which is a common side effect of RAASi therapy.
A team of UTSA researchers has developed an innovative inhibitor that blocks the effects of cytochrome P450 8B1, a key enzyme linked to cholesterol absorption and obesity. The treatment shows promise in reducing glucose levels without affecting body weight, offering potential relief from obesity-associated metabolic disorders.
The article suggests a potential treatment option for COVID-19 by targeting SARS-CoV-2's interaction with ACE2 receptors. Combining DPP4 inhibitors and spironolactone may mitigate COVID-19 complications and infections without adverse side effects.
A team of researchers at MedUni Vienna's Center for Physiology and Pharmacology has discovered a key building block in immune cells that promotes immunotolerance and prevents T-cell attacks on the body's own tissues. The study suggests a potential new cell-based therapeutic approach to slow down autoimmune disease progression.
Researchers discovered that inhibiting the breakdown of a neuroprotective molecule called 2-arachidonoylglycerol (2-AG) in astrocytes promotes recovery from traumatic brain injury. The study suggests that targeting this molecule could lead to the development of new therapies for TBI-induced disease.
Research from the University of Virginia Health System found that long-term use of ACE inhibitors and angiotensin receptor blockers can lead to hardened kidney vessels. The drugs, commonly prescribed for high blood pressure and heart failure, were associated with damage in both lab mice and humans.
Scientists from Japan discover IL-36Ra plays a pivotal role in wound healing, and Cl-amidine normalizes exacerbated I/R injury. The study's findings suggest IL-36Ra as a potential therapeutic target for cutaneous I/R injuries.
Scientists have identified the molecular origins of recombination in RNA viruses, a process that can lead to the emergence of new variants. The study reveals a new class of antiviral drugs that target this mechanism, but warns of potential risks when used in large quantities.
Researchers at Gladstone Institutes found that reducing tau levels impacts both excitatory and inhibitory cells, leading to a reduction in excitation-inhibition ratios. This effect counteracts diseases that cause abnormal increases in this ratio, potentially improving the brain's ability to perform its functions.
Researchers found a chemical inhibitor of PDE9 stimulates cells to burn more fat in mice, reducing obesity and fatty liver. The study's findings suggest the experimental drug may be effective in treating severe obesity and improving heart function.
Researchers from Kazan Federal University discovered that micelle-forming polyurethane inhibitors can effectively inhibit hydrate formation. The study found that the presence of surface-active properties and ability to form micelles can hinder hydrate formation, providing a new mechanism for gas storage and flow assurance.
SGLT2 inhibitors like gliflozins reduce the risk of progressing to end-stage kidney disease in both diabetic and non-diabetic patients. The kidneys produce less erythropoietin as a result, which reduces anemia, resulting in reduced renal endpoint, cardiovascular events, and mortality
This study identifies potential anti-COVID-19 pharmacological components of TCM's Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. The research demonstrates the utility of this approach for identifying pharmaceutically active components in Chinese herb medicines.
A study published in the Journal of General Virology found that curcumin can prevent TGEV infection and kill virus particles. This antiviral property could be beneficial in preventing diseases caused by TGEV in piglets.
A new study launched by Clínica Universidad de Navarra and the Barcelona Institute for Global Health aims to determine if ivermectin can reduce viral replication in patients with mild COVID-19. The trial, which will be conducted at home, will monitor symptoms and nasal swabs over a month-long period.
A team led by Michael Kyba identified an inhibitor that protects cells from toxic effects associated with facioscapulohumeral muscular dystrophy (FSHD) in cells and mice. The compound, iP300w, blocks the p300 enzyme needed by the DUX4 protein, preventing its toxic effects.
A new review of scientific literature suggests that medium doses of ADHD medication have the strongest beneficial effects on inhibitory control, a key aspect of impulsiveness. Increasing doses beyond this point may not make a significant difference in symptoms.
Researchers at Max Planck Florida Institute for Neuroscience developed a strategy to label and map local inhibitory inputs onto cells. They found that inhibitory inputs may parallel or diverge from target neurons, revealing a diverse palette of inhibition. This discovery suggests complex functional connectivity in the visual cortex.
Researchers found that using high UVA protection factor sunscreen allows for better vitamin D synthesis due to increased UVB transmission. Despite concerns, optimal sunscreen use does not harm vitamin D production, according to a new study published in the British Journal of Dermatology.
Median nerve stimulation triggers release of neuropeptide orexin from hypothalamus, leading to reduced inhibitory control in midbrain's pain-control region. This analgesic effect depends on endocannabinoid receptors, not opioid receptors.
Researchers find that glucitol-core-containing gallotannins from red maple leaves can block elastase activity, maintaining skin elasticity. The findings could lead to the development of plant-based skincare products and create new economic opportunities for farmers in eastern North America.
A study published in Journal of Clinical Investigation found that adult-onset progressive degenerative diseases have their roots in early developmental defects. Researchers used a mouse model of spinocerebellar ataxia type 1 and discovered altered neural circuitry in the cerebellum, which sets the stage for later disease vulnerability.
Researchers at Aarhus University have developed a llama-antibody, or nanobody, that can prevent the cleavage of the C3 protein, which plays a crucial role in the innate immune system. This breakthrough could lead to new treatments for kidney diseases and conditions where the immune system is overactive.
A single-center study found that cancer immunotherapy is safe for patients with rheumatologic diseases, with only a minority experiencing adverse effects. The treatment was successfully administered to all six affected patients, paving the way for its use in select groups with pre-existing conditions.
Researchers developed a neutralizing agent for CSPGs that inhibit oligodendrocyte migration and differentiation. Protamine was found to inhibit CSPG-mediated inhibition of oligodendrocyte differentiation, enhancing myelination in the developing mouse brain and remyelination in adult mice.